Survodutide cardiovascular safety trial meets its goal as one in five stop for stomach side effects
SYNCHRONIZE CVOT found the glucagon and GLP 1 drug did not raise heart risk in 5,507 high risk adults, but did not show a benefit. About 20% on survodutide quit for gastrointestinal effects, and the lead investigator wants flexible titration.
What's new
Full SYNCHRONIZE CVOT results show survodutide was noninferior to placebo for major heart events in 5,507 high risk adults, and the lead investigator now urges flexible, individual dose escalation.
Why it matters
It is the first large heart safety trial of a glucagon and GLP 1 drug, but it shows no heart benefit, and about one in five patients on the drug stopped for stomach side effects.
What's next
Boehringer Ingelheim says it will pursue regulatory submissions for survodutide in obesity worldwide; no filing date has been announced.
Survodutide cardiovascular safety data from the Phase 3 SYNCHRONIZE CVOT trial show the Boehringer Ingelheim drug did not raise heart risk against placebo, but about one in five patients on it stopped treatment because of stomach side effects. The trial's principal investigator, Biykem Bozkurt of Baylor College of Medicine, told Pharmacy Times on 17 November that dose escalation should be fitted to each patient. The full results were presented on 9 November at the American Heart Association meeting in Chicago and published the same day in The Lancet.
What SYNCHRONIZE CVOT measured
Survodutide is an investigational once weekly injection that acts on both the glucagon and GLP 1 receptors. SYNCHRONIZE CVOT, registered as NCT06077864, was a randomized, double blind, event driven trial designed to test safety rather than benefit. It randomized 5,530 adults, and 5,507 received at least one dose, split almost evenly between two survodutide dose levels and placebo. Everyone had a body mass index of at least 27 plus established heart disease, chronic kidney disease, or at least two weight related conditions or risk factors. According to Healio, mean age was 60.8 years, 39.8% were women, mean body mass index was 36.5 and 52.7% had type 2 diabetes. Median time in the study was 22 months, Patient Care reported. Boehringer funded the trial.
The primary endpoint counted the first of five events: cardiovascular death, nonfatal heart attack, nonfatal stroke, coronary revascularization or a heart failure event. Regulators ask for this kind of trial for new classes of weight loss drugs, as they do for diabetes drugs, Bozkurt told Pharmacy Times. The question is narrow. A noninferiority test asks only whether the drug is no worse than placebo by a preset margin, not whether it prevents events. Boehringer describes SYNCHRONIZE CVOT as the first global cardiovascular safety trial of a drug that targets both glucagon and GLP 1, a company claim. Survodutide is not approved anywhere, and the company says it intends to pursue regulatory submissions for obesity worldwide.
Survodutide cardiovascular safety results
The primary composite event occurred in 136 of 3,671 people on survodutide, or 3.7%, and in 76 of 1,836 on placebo, or 4.1%, according to Patient Care. The hazard ratio was 0.89, with a 95% confidence interval of 0.67 to 1.18, which met the test for noninferiority. The narrower three part measure of cardiovascular death, heart attack and stroke gave a hazard ratio of 0.84, with an interval of 0.60 to 1.18. Both intervals cross 1. That means the trial rules out a meaningful rise in risk but does not show a benefit. Ashish Sarraju of Cleveland Clinic, commenting to Healio, said "we cannot tell patients that this is going to improve their CV risk."
That means the trial rules out a meaningful rise in risk but does not show a benefit.
Bozkurt pointed to a second analysis. When follow up counted only time that patients were actually taking the drug, the hazard ratio for the main endpoint fell to 0.75, with a confidence interval of 0.53 to 1.06, Healio reported. She said the point estimates moved in a more favorable direction for people who stayed on therapy, but she stressed that the trial "was not powered" to test superiority. That on treatment view is a secondary lens. It drops the time after people stopped, and the people who stop are not a random group, so the figure cannot be read as proof of protection. Its interval also still crosses 1. A trial built to test benefit would be needed to settle the point.
Weight loss and the stomach side effects
The drug's metabolic effects were large. At 72 weeks, in a supplementary analysis, body weight fell by up to 13.7% on survodutide against 2.0% on placebo, Pharmacy Times reported. Waist size shrank by up to 11.96 centimeters against 2.74, and systolic blood pressure fell by up to 6.68 mm Hg against 1.76. Boehringer also reported lower inflammation and triglyceride markers but did not release those figures. Tolerability was the weak spot. Nausea, vomiting, diarrhea and constipation were the most common side effects, mostly mild to moderate. The table sets out the main results, with the source of each figure, since not every outlet reported the same set of numbers from the Lancet paper.
| Measure | Survodutide | Placebo | Reported by |
|---|---|---|---|
| Five part heart endpoint events | 3.7% | 4.1% | Patient Care |
| Hazard ratio, five part endpoint | 0.89 (0.67 to 1.18) | reference | Patient Care |
| Hazard ratio, three part endpoint | 0.84 (0.60 to 1.18) | reference | Patient Care |
| Weight change at 72 weeks | up to minus 13.7% | minus 2.0% | Pharmacy Times |
| Stopped for stomach side effects | 19.3% and 20.8% by dose | 1.9% | Pharmacy Times |
Discontinuation because of gastrointestinal events reached 19.3% on the lower dose and 20.8% on the higher dose, against 1.9% on placebo. Most of those stops came during dose escalation, Pharmacy Times reported, and the original protocol allowed little room to slow titration, lower a dose or pause. Bozkurt said the SYNCHRONIZE program first required a fixed escalation schedule over 24 weeks. In her view, titration should depend on each patient's tolerability and ability to stay on a dose. Later flexibility in SYNCHRONIZE CVOT allowed more participants to remain on the drug, she said. Nausea control is a wider problem for the whole class, as shown by a recent Phase 3 test of tradipitant against vomiting after semaglutide.
What the trial means for pharmacists and patients
Bozkurt told Pharmacy Times that pharmacists are central to spotting each patient's needs, tolerance and side effects during dose increases. She also raised a point that affects how trial results are read. Some people in the placebo group took other marketed weight loss products during the study, she said, and clinicians should know what patients take over the counter or as compounded products. That kind of drop in use can shrink the measured gap between drug and placebo. It also links to safety questions about compounded peptide products, which have no approved label and no trial record behind them. Bozkurt urged pharmacists to talk about heart and metabolic health with patients rather than the size of weight loss alone.
She said people with obesity should be screened for diabetes, fatty liver disease, chronic kidney disease, abnormal blood fats, high blood pressure and heart disease. She also cited a separate abstract at the meeting showing that survodutide helped participants reach targets for blood fats, HbA1c, waist size and blood pressure sooner than placebo, though no figures were given in the interview. The Healio report on the trial lists Bozkurt as a consultant to several companies, including Boehringer. Survodutide cardiovascular safety data will now go into the filing package that Boehringer plans for obesity, with no submission date announced. Earlier trial coverage sits on the Peptide Zone trials desk.
Conclusion
The survodutide cardiovascular safety trial cleared its main hurdle: the drug did not raise heart risk in more than 5,500 high risk adults. It did not show heart protection, and roughly one in five patients on survodutide stopped because of stomach side effects, mostly during dose increases. Flexible titration may help, but that has not been tested as a trial endpoint. A regulatory decision will weigh weight loss gains against that tolerability record.